Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands

Highlights • GClb appeared to be a cost-effective treatment strategy compared to RClb and Clb • The ICERs of GClb compared to RClb and Clb were €23,208 and €7,254 per QALY • Indirect treatment comparisons showed favourable ICERs for GClb compared to OClb • The ICERs of GClb compared to OClb varied f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2016-11, Vol.50, p.37-45
Hauptverfasser:	Blommestein, Hedwig M, Groot, Saskia de S, Aarts, Mieke J, Vemer, Pepijn, Vries, Robin De, Abeelen, Annet FMVan, Posthuma, EFMWard, Groot, Carin AUyl-de
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chlorambucil Chlorambucil - therapeutic use Chronic lymphocytic leukaemia Cost-Benefit Analysis - methods Cost-effectiveness Costs Hematology, Oncology and Palliative Medicine Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - economics Markov Chains Netherlands Obinutuzumab Ofatumumab Quality-Adjusted Life Years Rituximab Rituximab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • GClb appeared to be a cost-effective treatment strategy compared to RClb and Clb • The ICERs of GClb compared to RClb and Clb were €23,208 and €7,254 per QALY • Indirect treatment comparisons showed favourable ICERs for GClb compared to OClb • The ICERs of GClb compared to OClb varied from €6,556 to €16,180 per QALY
ISSN:	0145-2126 1873-5835
DOI:	10.1016/j.leukres.2016.09.005